Vyro Bio

About:

Vyro develops oncolytic viruses designed to target CNS tumors, based on pioneering research on the oncolytic properties of the Zika Virus.

Website: https://www.vyrobio.com

Top Investors: Vesper Ventures SA

Description:

Vyro is an immuno-oncology (I-O) biotechnology company developing cancer-killing, or ‘oncolytic’, viruses (OVs) designed to target adult and pediatric central nervous system (CNS) tumors, based on pioneering research and breakthrough discovery of the oncolytic properties of the Zika Virus (ZIKV).

Total Funding Amount:

$1.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

São Paulo, Sao Paulo, Brazil

Founded Date:

2021-02-25

Contact Email:

carolini.kaid(AT)vyrobio.com

Founders:

Carolini Kaid, Hugo Cabrera

Number of Employees:

11-50

Last Funding Date:

2022-02-19

IPO Status:

Private

Industries: